Insmed Incorporated (INSM) Fair Value 2026

INSM · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.7 /10

32 fundamental signals · 2 models active

Value Trap Risk

SAFE (18/100)

Quick Summary — As of 2026-08-28, Insmed Incorporated (INSM) trades at $118.54, versus a $5.05 median fair value across its 2 active models — 95.7% below the current price. QOC: 6.7/10. Value Trap Risk: 18/100 (SAFE). 2/13 models active.

Key Facts

Ticker
INSM
Price
$118.54
Quality Score
6.7/10
Value Trap Risk
18/100
Models Active
2/13
Last Updated
Strength: 2 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

Is Insmed Incorporated (INSM) Undervalued or Overvalued in 2026?

According to CirclFi’s 2-model valuation engine, Insmed Incorporated (INSM) appears overvalued as of : the median of 2 independent fair value estimates is $5.05, 95.7% below the current price of $118.54. Estimates range from $4.78 to $5.32. INSM scores 6.7/10 on fundamental quality and 18/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. INSM’s -95.7% gap is wider than that market norm, and the Biotechnology sector median is -64.7%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Insmed Incorporated Stock in 2026? →

What Fair Value Does Each Model Give INSM?

2 Intrinsic Value Models vs. Current Price ($118.54)

Core Models (Unlocked)
Model Fair Value Upside
Relative · Medium Conviction
 $4.78 -96.0%
Relative · Low Conviction
 $5.32 -95.5%

All Models Active

All 2 models are displayed above.

What Is Insmed Incorporated (INSM) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Insmed Incorporated's intrinsic value is estimated at $5.05, suggesting the stock is overvalued at its current price of $118.54. With 2 out of 2 models flagging downside (-95.7% vs price), the market may be pricing in unsustainable growth.

What Do the Models Say About INSM?

2 of 13 models are currently active for INSM. All 2 active models suggest the stock trades above fair value. Taken together, their median fair value for INSM is $5.05 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does INSM Rank in Biotechnology?

Among 625 Biotechnology stocks, INSM ranks #69 by Quality of Company score. CirclFi's QOC score of 6.7/10 evaluates 32 fundamental signals. A score of 6.7 indicates above-average quality.

See all Most Undervalued Biotechnology Stocks →

As a biotechnology enterprise, Insmed Incorporated operates in a sector where pipeline depth and stage distribution is a critical driver of valuation. Investors evaluating INSM should weigh these sector-specific dynamics alongside our model-derived fair values.

Is INSM a Value Trap?

CirclFi's Value Trap algorithm assigns INSM a score of 18/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

2 of 13 models are active for Insmed Incorporated. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Insmed Incorporated's fundamental quality profile registers 6.7/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

Models cluster within a tight range (+0.5% spread), increasing conviction. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every INSM valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across INSM's 2 active models, average confidence is 26%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Insmed Incorporated Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

LEGNLegend Biotech CorporationQOC 6.7CRNXCrinetics Pharmaceuticals, Inc.QOC 6.7BCYCBicycle Therapeutics plcQOC 6.7RCUSArcus Biosciences, Inc.QOC 6.7MDGLMadrigal Pharmaceuticals, Inc.QOC 6.7FENCFennec Pharmaceuticals Inc.QOC 6.7VRCAVerrica Pharmaceuticals Inc.QOC 5.4ANNXAnnexon, Inc.QOC 4.8BCABBioAtla, Inc.QOC 4.0EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: LEGN · CRNX · BCYC · RCUS · MDGL · FENC · VRCA · ANNX · BCAB · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to INSM?

7 companies across all industries closest to INSM’s Quality of Company score of 6.7/10.

DSNYDestiny Media Technologies Inc.QOC 6.7MTUSMetallus Inc.QOC 6.7NEWTNewtekOne, Inc.QOC 6.7KTKT CorporationQOC 6.7RCELAVITA Medical, Inc.QOC 6.7SOThe Southern CompanyQOC 6.7NVDANVIDIA CorporationQOC 10.0

Read investment analysis: DSNY · MTUS · NEWT · KT · RCEL · SO · NVDA

Where Does INSM Sit in CirclFi's Biotechnology Rankings?

INSM is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Insmed Incorporated’s Valuation?

What is Insmed Incorporated's intrinsic value in 2026?

CirclFi puts Insmed Incorporated (INSM)'s intrinsic value at $5.05 — the median of 2 independent model estimates as of 2026-08-28, ranging from $4.78 to $5.32. The Quality of Company score is 6.7/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is INSM overvalued or undervalued right now?

At $118.54, 0 of 2 active models suggest INSM may be undervalued, while 2 indicate potential overvaluation. The median of all 2 fair value estimates is $5.05, 95.7% below the current price of $118.54 — a consensus view that INSM is overvalued. The assessment depends on which methodology best fits Insmed Incorporated's business model in Biotechnology.

What does a Quality of Company score of 6.7 mean for INSM?

Insmed Incorporated's QOC of 6.7/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on INSM?

CirclFi analyzes INSM with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 2 of 13 are active for this stock. Read the full methodology →

Is INSM a value trap in 2026?

Insmed Incorporated's Value Trap score is 18/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 2-model valuation engine, Insmed Incorporated (INSM) has a median fair value of $5.05 — 95.7% below the current price of $118.54 — as of 2026-08-28.” Source: circlfi.com/stock/INSM/ · Methodology
Primary sources for this INSM valuation
  • Financial statements: Insmed Incorporated 10-K and 10-Q filings on SEC EDGAR (CIK 0001104506) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for INSM as of ; valuations recomputed .